Myoinositol trispyrophosphate

Drug Profile

Myoinositol trispyrophosphate

Alternative Names: OXY 111A

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NormOxys
  • Developer NormOxys; University of Zurich
  • Class Cyclohexanes; Small molecules; Sugar alcohols
  • Mechanism of Action Haemoglobin modulators; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Chronic heart failure; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA (IV, Infusion)
  • 28 Aug 2015 No development reported - Preclinical for Obesity in USA (IV)
  • 25 Aug 2015 No development reported - Phase-I for Chronic heart failure in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top